Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-03-2017 | Review Article

The Laboratory Diagnosis of the Antiphospholipid Syndrome

Authors: Jasmina Ahluwalia, Sreejesh Sreedharanunni

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2017

Abstract

The Antiphospholipid Syndrome (APS) is classified based on the presence of both clinical and laboratory criteria. Both sets of criteria are subject to much review and intense research as it is becoming increasingly clear that no single test is specific for defining this autoimmune disorder. A number of leading international bodies have released guidelines in an attempt to improve the laboratory testing and reporting. The current review is an appraisal of some of the literature pertaining to the laboratory testing.

Khamashta M, Hughes GRV (1999) Hughes syndrome: a short history of the antiphospholipid syndrome. In: Schoenfeld Y (ed) The decade of autoimmunity. Elsevier Science BV

Nayfe R, Uthman I, Aoun J, SaadAldin E, Merashli M, Khamashta MA (2013) Seronegative antiphospholipid syndrome. Rheumatology (Oxf Engl) 52:1358–1367CrossRef

Meroni PL, Chighizola CB, Rovelli F, Gerosa M (2014) Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther 16:1–14CrossRef

Forastiero R (2012) Bleeding in the antiphospholipid syndrome. Hematology (Amst Neth) 17(Suppl 1):153–155

de Groot PG, Urbanus RT, Derksen RHWM (2012) Pathophysiology of thrombotic APS: Where do we stand? Lupus 21:704–707CrossRefPubMed

Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:1033–1044CrossRefPubMed

de Groot PG, Meijers JCM (2011) β(2)–Glycoprotein I: evolution, structure and function. J Thromb Haemost JTH 9:1275–1284CrossRefPubMed

Krilis SA, Giannakopoulos B (2014) Laboratory methods to detect antiphospholipid antibodies. Hematol Am Soc Hematol Educ Program 2014:321–328

de Groot PG, Urbanus RT (2012) The significance of autoantibodies against β2-glycoprotein I. Blood 120:266–274CrossRefPubMed

10.

Lackner KJ, Müller-Calleja N (2016) Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma. J Thromb Haemost JTH 14:1117–1120CrossRefPubMed

11.

Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311CrossRefPubMed

12.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH 4:295–306CrossRefPubMed

13.

Cousins L, Pericleous C, Khamashta M, Bertolaccini ML, Ioannou Y, Giles I et al (2015) Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with “seronegative” antiphospholipid syndrome. Ann Rheum Dis 74:317–319CrossRefPubMed

14.

Pengo V, Testa S, Martinelli I, Ghirarduzzi A, Legnani C, Gresele P et al (2015) Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 135:46–49CrossRefPubMed

15.

Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F et al (2011) Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118:4714–4718CrossRefPubMed

16.

Mustonen P, Lehtonen KV, Javela K, Puurunen M (2014) Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus 23:1468–1476CrossRefPubMed

17.

de Groot PG, Lutters B, Derksen RHWM, Lisman T, Meijers JCM, Rosendaal FR (2005) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost JTH 3:1993–1997CrossRefPubMed

18.

de Laat B, Derksen RHWM, Urbanus RT, de Groot PG (2005) IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105:1540–1545CrossRefPubMed

19.

Banzato A, Pozzi N, Frasson R, De Filippis V, Ruffatti A, Bison E et al (2011) Antibodies to domain I of β(2)Glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res 128:583–586CrossRefPubMed

20.

Pengo V, Banzato A, Denas G, Jose SP, Bison E, Hoxha A et al (2013) Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 12:832–834CrossRefPubMed

21.

Forastiero R (2014) Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus 23:1252–1254CrossRefPubMed

22.

Park SH, Jang S, Park C-J, Chi H-S (2016) Clinical application of revised laboratory classification criteria for antiphospholipid antibody syndrome: Is the follow-up interval of 12 weeks instead of 6 weeks significantly useful? BioMed Res Int 2016:2641526PubMedPubMedCentral

23.

Pengo V, Denas G, Padayattil SJ, Zoppellaro G, Bison E, Banzato A et al (2015) Diagnosis and therapy of antiphospholipid syndrome. Pol Arch Med Wewn 125:672–677PubMed

24.

Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M et al (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost JTH 7:1737–1740CrossRefPubMed

25.

Rand JH, Wolgast LR (2012) Dos and don’ts in diagnosing antiphospholipid syndrome. Hematol Am Soc Hematol Educ Program 2012:455–459

26.

Devreese KMJ, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL et al (2014) Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 12:792–795CrossRefPubMed

27.

Keeling D, Mackie I, Moore GW, Greer IA, Greaves M (2012) British Committee for Standards in haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 157:47–58CrossRefPubMed

28.

Moore GW (2014) Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 40(2):163–171CrossRefPubMed

29.

De Craemer AS, Musial J, Devreese KM (2016) Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost 14(9):1779–1787. doi:10.1111/jth.13389 CrossRefPubMed

30.

Simmons DP, Herskovits AZ, Battinelli EM, Schur PH, Lemire SJ, Dorfman DM (2016) Lupus anticoagulant testing using two parallel methods detects additional cases and predicts persistent positivity. Clin Chem Lab Med. doi:10.1515/cclm-2015-0790. pii: /j/cclm.ahead-of-print/cclm-2015-0790/cclm-2015-0790.xmlPubMed

31.

Ahluwalia J, Sreedharanunni S, Kumar N, Masih J, Bose SK, Varma N et al (2016) Thrombotic primary antiphospholipid syndrome: the profile of antibody positivity in patients from North India. Int J Rheum Dis 19(9):903–912CrossRefPubMed

32.

Meneghel L, Ruffatti A, Gavasso S, Tonello M, Mattia E, Spiezia L et al (2015) The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clin Chem Lab Med 53:1083–1089CrossRefPubMed

33.

Oku K, Amengual O, Kato M, Bohgaki T, Horita T, Yasuda S et al (2016) Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. Thromb Res 146:1–6CrossRefPubMed

34.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2015) The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxf Engl) 54:134–138CrossRef

35.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2013) GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxf Engl) 52:1397–1403CrossRef

36.

Sciascia S, Cuadrado MJ, Sanna G, Murru V, Roccatello D, Khamashta MA et al (2014) Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res 66:1915–1920CrossRef

Title: The Laboratory Diagnosis of the Antiphospholipid Syndrome
Authors: Jasmina Ahluwalia
Sreejesh Sreedharanunni
Publication date: 01-03-2017
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 1/2017
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-016-0739-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Coexistent Multiple Myeloma and SLL: A Rare Entity

Outcome of Cyclosporine Monotherapy in Patients of Aplastic Anemia: Experience of a Tertiary Care Hospital in Eastern India

Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy

Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases

Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India

Two Cases of NK/T Cell Lymphoma Presenting as Chronic Rhinosinusitis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer